SLC2A5 and neoplasm: Pu et al. developed a dual-targeted liposome specifically targeting GLUT5 and integrin αvβ3, demonstrating enhanced drug uptake and accumulation within tumor sites in triple-negative breast cancer; these results emphasize GLUT5 as a promising therapeutic target capable of improving treatment efficacy 143.